Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis.
Because it plays a central role in the immunopathogenesis of rheumatoid arthritis (RA), TNF-alpha is an attractive target for immunomodulatory therapy. In a number of rigorous studies, monoclonal antibodies (mAb) specific for TNF-alpha have proved efficacious in patients with active RA. Data from these studies and issues related to mechanisms of action, potential toxicity, and future directions for this novel therapeutic approach are considered in this review.
University of Texas, Southwestern Medical School, Dallas, USA. akavan@mednet.swmed.edu
A F
AF
Kavanaugh
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology* / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha